Skip to main content
SpringerLink
Log in

Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney

A Southwest Oncology Group study

  • Brief Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The Southwest Oncology Group studied the response rate and toxicity of didemnin B (3.47 mg/m2 i.v. q 28 days) in patients with advanced renal cell carcinoma. There were no responses in 22 response evaluable patients. Toxicity was significant with 10 patients having grade 3 or 4 toxicity. Toxicity seen included nausea and vomiting, exacerbation of coronary artery disease, hyperglycemia, anorexia, diarrhea and hepatitis. Didemnin B was toxic but inactive in patients with renal cell treated at this dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rhineart KL Jr, Grever JB, Hughes RG Jr, Swynenberg EB, Stringfellow DA, Kuentzel SL, Li LH: Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 212:933, 1981

    Google Scholar 

  2. Dorr FA, Kuhn JG, Philips J, Von Hoff DD: Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide. Eur J Cancer Clin Oncol 24:1699, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Kansas Medical Center, Kansas City, KS, USA

    Sarah A. Taylor & Ronald L. Stephens

  2. Southwest Oncology Group Statistical Center, Seattle, WA, USA

    Phyllis Goodman

  3. University of Colorado, Denver, CO, USA

    E. David Crawford

  4. Tulane University Medical Center, New Orleans, LA, USA

    W. J. Stuckey

  5. Loyola University Stritch School of Medicine, Maywood, IL, USA

    Ellen R. Gaynor

Authors
  1. Sarah A. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Phyllis Goodman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. David Crawford
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. J. Stuckey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ronald L. Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ellen R. Gaynor
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taylor, S.A., Goodman, P., Crawford, E.D. et al. Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. Invest New Drugs 10, 55–56 (1992). https://doi.org/10.1007/BF01275484

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01275484

Key words

Search

Navigation